Original article
Cost minimisation analysis of fingolimod vs. natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
Análisis de minimización de costes entre fingolimod y natalizumab en segunda línea de tratamiento de esclerosis múltiple remitente-recurrente
a Departamento de Estadística, Universidad de Barcelona, Barcelona, Spain
b Oblikue Consulting, Barcelona, Spain
c Unidad de Esclerosis Múltiple, Hospital Universitario Virgen de la Macarena, Sevilla, Spain
d Departamento de Farmacología y Terapéutica Clínica, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
e Novartis Farmacéutica, Barcelona, Spain
Read
5657
Timeswas read the article
1328
Total PDF
4329
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 176 | 20 | 196 |
| 2025 11 | 119 | 35 | 154 |
| 2025 10 | 122 | 7 | 129 |
| 2025 9 | 113 | 30 | 143 |
| 2025 8 | 124 | 12 | 136 |
| 2025 7 | 84 | 9 | 93 |
| 2025 6 | 95 | 7 | 102 |
| 2025 5 | 76 | 7 | 83 |
| 2025 4 | 88 | 9 | 97 |
| 2025 3 | 81 | 6 | 87 |
| 2025 2 | 49 | 2 | 51 |
| 2025 1 | 91 | 4 | 95 |
| 2024 12 | 46 | 6 | 52 |
| 2024 11 | 61 | 5 | 66 |
| 2024 10 | 36 | 6 | 42 |
| 2024 9 | 55 | 21 | 76 |
| 2024 8 | 55 | 14 | 69 |
| 2024 7 | 44 | 10 | 54 |
| 2024 6 | 25 | 6 | 31 |
| 2024 5 | 38 | 11 | 49 |
| 2024 4 | 45 | 11 | 56 |
| 2024 3 | 47 | 10 | 57 |
| 2024 2 | 35 | 4 | 39 |
| 2024 1 | 39 | 14 | 53 |
| 2023 12 | 28 | 19 | 47 |
| 2023 11 | 36 | 8 | 44 |
| 2023 10 | 32 | 15 | 47 |
| 2023 9 | 11 | 0 | 11 |
| 2023 8 | 14 | 4 | 18 |
| 2023 7 | 7 | 8 | 15 |
| 2023 6 | 19 | 9 | 28 |
| 2023 5 | 11 | 2 | 13 |
| 2023 4 | 13 | 2 | 15 |
| 2023 3 | 15 | 4 | 19 |
| 2023 2 | 9 | 1 | 10 |
| 2023 1 | 13 | 12 | 25 |
| 2022 12 | 20 | 5 | 25 |
| 2022 11 | 30 | 6 | 36 |
| 2022 10 | 20 | 9 | 29 |
| 2022 9 | 19 | 7 | 26 |
| 2022 8 | 15 | 9 | 24 |
| 2022 7 | 14 | 12 | 26 |
| 2022 6 | 14 | 6 | 20 |
| 2022 5 | 11 | 6 | 17 |
| 2022 4 | 33 | 9 | 42 |
| 2022 3 | 39 | 11 | 50 |
| 2022 2 | 42 | 6 | 48 |
| 2022 1 | 39 | 9 | 48 |
| 2021 12 | 27 | 14 | 41 |
| 2021 11 | 24 | 9 | 33 |
| 2021 10 | 74 | 8 | 82 |
| 2021 9 | 29 | 12 | 41 |
| 2021 8 | 25 | 8 | 33 |
| 2021 7 | 18 | 9 | 27 |
| 2021 6 | 17 | 6 | 23 |
| 2021 5 | 16 | 6 | 22 |
| 2021 4 | 45 | 9 | 54 |
| 2021 3 | 15 | 11 | 26 |
| 2021 2 | 18 | 6 | 24 |
| 2021 1 | 8 | 9 | 17 |
| 2020 12 | 12 | 6 | 18 |
| 2020 11 | 5 | 9 | 14 |
| 2020 10 | 14 | 5 | 19 |
| 2020 9 | 12 | 10 | 22 |
| 2020 8 | 13 | 7 | 20 |
| 2020 7 | 15 | 10 | 25 |
| 2020 6 | 6 | 6 | 12 |
| 2020 5 | 16 | 9 | 25 |
| 2020 4 | 7 | 1 | 8 |
| 2020 3 | 21 | 7 | 28 |
| 2020 2 | 22 | 6 | 28 |
| 2020 1 | 12 | 12 | 24 |
| 2019 12 | 22 | 13 | 35 |
| 2019 11 | 7 | 5 | 12 |
| 2019 10 | 18 | 7 | 25 |
| 2019 9 | 14 | 1 | 15 |
| 2019 8 | 27 | 6 | 33 |
| 2019 7 | 31 | 11 | 42 |
| 2019 6 | 28 | 17 | 45 |
| 2019 5 | 78 | 45 | 123 |
| 2019 4 | 27 | 28 | 55 |
| 2019 3 | 16 | 5 | 21 |
| 2019 2 | 13 | 10 | 23 |
| 2019 1 | 12 | 8 | 20 |
| 2018 12 | 7 | 8 | 15 |
| 2018 11 | 16 | 4 | 20 |
| 2018 10 | 25 | 21 | 46 |
| 2018 9 | 12 | 6 | 18 |
| 2018 8 | 5 | 1 | 6 |
| 2018 7 | 7 | 2 | 9 |
| 2018 6 | 5 | 5 | 10 |
| 2018 5 | 8 | 4 | 12 |
| 2018 4 | 1 | 6 | 7 |
| 2018 3 | 10 | 4 | 14 |
| 2018 2 | 12 | 7 | 19 |
| 2018 1 | 4 | 2 | 6 |
| 2017 12 | 15 | 2 | 17 |
| 2017 11 | 15 | 2 | 17 |
| 2017 10 | 11 | 2 | 13 |
| 2017 9 | 12 | 4 | 16 |
| 2017 8 | 20 | 5 | 25 |
| 2017 7 | 9 | 2 | 11 |
| 2017 6 | 21 | 9 | 30 |
| 2017 5 | 21 | 2 | 23 |
| 2017 4 | 16 | 2 | 18 |
| 2017 3 | 12 | 47 | 59 |
| 2017 2 | 12 | 2 | 14 |
| 2017 1 | 14 | 4 | 18 |
| 2016 12 | 29 | 9 | 38 |
| 2016 11 | 25 | 12 | 37 |
| 2016 10 | 46 | 7 | 53 |
| 2016 9 | 35 | 13 | 48 |
| 2016 8 | 13 | 6 | 19 |
| 2016 7 | 15 | 6 | 21 |
| 2016 6 | 28 | 12 | 40 |
| 2016 5 | 36 | 14 | 50 |
| 2016 4 | 35 | 17 | 52 |
| 2016 3 | 60 | 20 | 80 |
| 2016 2 | 45 | 20 | 65 |
| 2016 1 | 17 | 3 | 20 |
| 2015 12 | 23 | 6 | 29 |
| 2015 11 | 44 | 7 | 51 |
| 2015 10 | 27 | 9 | 36 |
| 2015 9 | 31 | 12 | 43 |
| 2015 8 | 12 | 12 | 24 |
| 2015 7 | 11 | 6 | 17 |
| 2015 6 | 14 | 4 | 18 |
| 2015 5 | 29 | 11 | 40 |
| 2015 4 | 29 | 13 | 42 |
| 2015 3 | 49 | 10 | 59 |
| 2015 2 | 34 | 10 | 44 |
| 2015 1 | 35 | 13 | 48 |
| 2014 12 | 35 | 12 | 47 |
| 2014 11 | 29 | 11 | 40 |
| 2014 10 | 30 | 18 | 48 |
| 2014 9 | 34 | 8 | 42 |
| 2014 8 | 42 | 8 | 50 |
| 2014 7 | 44 | 25 | 69 |
| 2014 6 | 34 | 17 | 51 |
| 2014 5 | 57 | 28 | 85 |
Show all
